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in type 2 than in type 1 diabetic mice: Roles of
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progenitor cells
Jinglian Yan, PhD,a Guodong Tie, PhD,a Brian Park, MD,a Yagai Yan, PhD,b Philip T. Nowicki, MD,a
and Louis M. Messina, MD,a Worcester, Mass; and South San Francisco, Calif
Objective:We sought to directly compare the effects of type 1 and type 2 diabetes on postischemic neovascularization and
evaluate the mechanisms underlying differences between these groups. We tested the hypothesis that type 2 diabetic mice
have a greater reduction in endothelial nitric oxide synthase (eNOS) expression, a greater increase in oxidative stress, and
reduced arteriogenesis and angiogenesis, resulting in less complete blood flow recovery than type 1 diabetic mice after
induction of hind limb ischemia.
Methods: Hind limb ischemia was generated by femoral artery excision in streptozotocin-treated mice (model of type 1
diabetes), in Leprdb/db mice (model of type 2 diabetes), and in control (C57BL/6) mice. Dependent variables included
eNOS expression and markers of arteriogenesis, angiogenesis, and oxidative stress.
Results: Postischemia recovery of hind limb perfusion was significantly less in type 2 than in type 1 diabetic mice; however,
neither group demonstrated a significant increase in collateral artery diameter or collateral artery angioscore in the
ischemic hind limb. The capillary/myofiber ratio in the gastrocnemiusmuscle decreased in response to ischemia in control
or type 1 diabetic mice but remained the same in type 2 diabetic mice. Gastrocnemius muscle eNOS expression was lower
in type 1 and 2 diabetic mice than in control mice. This expression decreased after induction of ischemia in type 2 but not
in type 1 diabetic mice. The percentage of endothelial progenitor cells (EPC) in the peripheral blood failed to increase in
either diabetic group after induction of ischemia, whereas this variable significantly increased in the control group in
response to ischemia. EPC eNOS expression decreased after induction of ischemia in type 1 but not in type 2 diabetic
mice. EPC nitrotyrosine accumulation increased after induction of ischemia in type 2 but not in type 1 diabetic mice. EPC
migration in response to vascular endothelial growth factor was reduced in type 1 and type 2 diabetic mice vs control mice.
EPC incorporation into tubular structures was less effective in type 2 diabetic mice. Extensive fatty infiltration was
present in ischemic muscle of type 2 but not in type 1 diabetic mice.
Conclusion: Type 2 diabetic mice displayed a significantly less effective response to hind limb ischemia than type 1 diabetic
mice. ( J Vasc Surg 2009;50:1412-22.)
Clinical Relevance:Diabetes is important in the pathogenesis of peripheral artery disease. The present study demonstrates that
the vascular response to acute hind limb ischemia is dependent on the type of diabetes present. Type 2 diabetic mice (Leprdb/db)
demonstrated significantly less effective blood flow recovery than type 1 diabeticmice (streptozotocin-induced).Moreover, the
differences between diabetic groups appeared contingent, at least in part, on differences in endothelial nitric oxide, oxidant
stress, and endothelial progenitor cell function between the two diabetic groups. Although direct extrapolation of animal data
to the human experience must be made with caution, these findings indicate that the type of diabetes present, and not just the
presence of diabetes per se, may be important in the initiation of progression of peripheral artery disease.From the University of Massachusetts Medical School, Department of
Surgery, Worcester,a and Genentech, South San Francisco.b
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1412Vascular dysfunction underlies many of the complications
of diabetes mellitus, including peripheral artery disease.1
However, the basis for this dysfunction is dissimilar in type 1
and type 2 diabetes. Type 1 diabetes is characterized by
hypoinsulinemia and profound hyperglycemia. The latter cir-
cumstance is particularly injurious to endothelial cells, which
lack the capacity to regulate glucose influx.1 Uncontrolled
glucose influx results in activation of protein kinase C and the
accumulation of advanced glycation end products and oxi-
dants within the endothelial cell, processes that instigate en-
dothelial dysfunction.1 In contrast, type 2 diabetes is charac-
terized by insulin resistance, moderate hyperglycemia, and an
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tion in type 2 diabetes reflects the effects of hypercholesterol-
emia and not just hyperglycemia on the endothelium.1-3
This distinction may be relevant in the design of treat-
ments for diabetic vascular disease, such as peripheral artery
disease. An important gap in knowledge, however, is the
lack of a direct comparison between the effects of type 1 and
2 diabetes on the response to vascular injury, that is, an
assessment that applies the identical experimental paradigm
to both types of diabetes.
Assessment of hind limb hemodynamics after ligation
or excision of the common femoral artery is a widely used
approach to study postischemic perfusion recovery and
neovascularization.4 By this means, Tamarat et al5 reported
significant compromise in postischemic hind limb flow
recovery in streptozotocin-induced type 1 diabetic mice,
whereas Emaueli et al6 described similar findings in the
Leprdb/db mouse model of type 2 diabetes. Methodologic
differences between these studies, however, preclude their
use as instruments to directly compare neovascularization
responses between types 1 and 2 diabetes.
Bone marrow-derived endothelial progenitor cells
(EPC) are critical participants in postischemic neovascular-
ization.7-9 EPC are mobilized from bone marrow and
home to sites of vascular injury, where they contribute to
arteriogenesis within existing collateral arteries and to an-
giogenesis within capillary networks. Dysfunction in EPC
mobilization and function has been reported in type 1 and
2 diabetes.10-13 Deficiencies in the generation of endothe-
lial nitric oxide synthase (eNOS)-derived nitric oxide14,15
and an increased level of oxidant stress16,17 have been
proposed as mechanisms responsible for EPC dysfunction
in diabetes. Again, however, direct comparison of these
circumstances between type 1 and 2 diabetes has not been
reported.
The goal of this study was to compare the effects of type
1 vs type 2 diabetes on blood flow recovery and neovascu-
larization after induction of severe hind limb ischemia using
streptozotocin-induced hypoinsulinemia as a model of type
1 diabetes and the Leprdb/db mouse as a model of type 2
diabetes. We tested the hypothesis that type 2 diabetic mice
have a greater reduction in eNOS expression, a greater
increase in oxidative stress, reduced arteriogenesis, and
angiogenesis resulting in less complete blood flow recovery
than type 1 diabetic mice after induction of hind limb
ischemia.
MATERIALS AND METHODS
Experimental animals. The mice used in this study
were obtained from Jackson Laboratories (Bar Harbor,
Me), were housed in an environmentally controlled room,
and were fed standard chow and water before and during
the course of study. The care of mice complied with the
National Research Council Guide for the Care and Use of
Laboratory Animals. All protocols were approved by the
Committees on Animal Research at the University of Cal-
ifornia, San Francisco, and the University of Massachusetts
Medical School.Antibodies and reagents. Streptozotocin, Dil-Ac-
LDL, Histopaque 1083, Matrigel, and the monoclonal
antibody for smooth muscle actin were obtained from
Sigma-Aldrich (St. Louis, Mo). Monoclonal antibodies for
CD31, eNOS, and nitrotyrosine were obtained from BD
Bioscience (San Diego, Calif). Monoclonal antibodies for
CD34, Flk-1, and CD133 were obtained from eBioscience
(San Jose, Calif). Vascular endothelial growth factor
(VEGF) was obtained from R&D Systems (Minneapolis,
Minn). Oil Red O was obtained from Poly Scientific (Bay
Shore, NY).
Experimental animals and procedures. C57BL/6
mice were used as the control group. Type 1 diabetes was
generated in 8-week-old C57BL/6 mice by an intraperito-
neal injection of streptozotocin (50 mg/kg daily for 5
days). Streptozotocin generates significant, predictable,
and reproducible hypoinsulinemia and profound hypergly-
cemia within 1 week after the onset of treatment. The
Leprdb/db (db/db) mouse, generated on a C57BL/6 back-
ground, was used as a model of type 2 diabetes. The db/db
mice are deficient in the Ob-Rb leptin receptor, critical in
regulation of satiety and hence food intake; consequently,
db/db mice become significantly obese. The db/db mice
fully express a type 2 diabetic phenotype of insulin resis-
tance, moderate hyperglycemia, and dyslipidemia by 2
months of age.18,19
Hind limb ischemia was induced as previously de-
scribed.20 Briefly, mice were anesthetized using 2% isoflu-
rane, and the left femoral artery and its associated branches
were isolated, ligated, and excised. The contralateral hind
limb served as an internal control within each mouse.
Measurement of hind limb blood flow. A laser
Doppler perfusion imager (Moor Instruments Ltd, Devon,
United Kingdom) was used to estimate dermal blood flow
in the calf and foot. Hind limb fur was removed by depila-
tory cream, and studies were conducted under 1.5% isoflu-
rane anesthesia. Mice were studied while on a heated sur-
face (37°C) and in a darkened room to minimize the effects
of ambient light and temperature on measurements. Blood
flow was expressed as a ratio of the ischemic and nonisch-
emic hind limbs.
Measurement of collateral artery enlargement and
number. At 28 days after induction of hind limb ischemia,
mice were anesthetized with 1.5% isoflurane, and a contrast
medium was injected into the abdominal aorta through a
catheter. Images were taken by a digital X-ray transducer.
Two observers independently scored the images by count-
ing the number of vessels that crossed a standardized grid
overlying the image. The number of vessels was divided by
the lines of the grid in the area of interest to produce an
angioscore. It was not possible to completely blind these
measurements because the obesity of the db/db type 2
diabetic mice was obvious on the radiographs.
Measurement of collateral artery diameter. Thigh
muscle was harvested 28 days after induction of ischemia
and frozen at 80°C in OCT. Cryosections (10 m) were
prepared and incubated with CD31 and smooth muscle
actin antibodies for the identification of endothelial cells
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arteries. Collateral artery diameter was measured using
precalibrated microscope scale bars. Three sections were
reviewed per animal, and collateral diameters were quanti-
fied in five randomly selected low-power (original magnifi-
cation 200) fields per section. The mean value of these
measurements was taken as a single data point for each
animal.
Measurement of capillary density. Gastrocnemius
muscle was harvested 28 days after induction of ischemia
and frozen at 80°C in OCT. Cryosections (10 m) were
prepared and incubated with CD31 antibody to identify
endothelial cells. Capillary density was expressed as the ratio of
CD31 cells tomyofibers. Thismeasurementwas determined
in five randomly selected low-power (original magnification
200) fields fromeach animal, and the average valuewas used
as a single data point for each mouse.
Assessment of muscle histology. Tibialis anterior
and gastrocnemius muscles were harvested on day 28 after
induction of ischemia, weighed, and frozen at 80°C in
OCT. Cryosections (10 m) were prepared and stained
with hematoxylin and eosin. To identify adipocytes, some
cryosections were fixed in 10% formalin for 10 minutes,
stained with Oil Red O at 60°C for 8 minutes and then
counterstained briefly with eosin. Five low-power (original
magnification200) fields were randomly selected on each
slide, and the degree of necrosis and adipocyte infiltration
noted in each.
Measurement of eNOS and nitrotyrosine. Muscle
tissue was harvested 7 days after induction of ischemia, and
EPCswere obtained frombonemarrow or peripheral blood 7
days after induction of ischemia. Tissue (muscle or EPC) was
homogenized in buffer (50 mM N-2-hydroxyethylpiperazine-
N=-2-ethanesulfonic acid [pH 7.5], 150 mM magnesium
chloride, 1 mM ethylenediaminetetraacetic acid, 100 mM
sodium chloride, 1% NP40). Protein extracts underwent
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), were transferred to pure nitrocellulose mem-
branes, and were probed with antibodies to eNOS, nitroty-
rosine, or -tubulin. Enhanced chemiluminescence detection
was used to visualize bands. Band intensity was determined by
densitometry. Densitometry data for the eNOS and nitroty-
rosine bands were expressed as a ratio to the -tubulin band.
Quantitation of EPC in bone marrow and periph-
eral blood. Samples of bone marrow and peripheral blood
were obtained 7 days after induction of ischemia. Mono-
nuclear cells were isolated by gradient centrifugation using
Histopaque 1083.Mononuclear cells (106) were incubated
for 10 minutes with monoclonal antibodies for CD34,
Flk-1, and CD133. Isotype antibodies were used as neg-
ative controls. Cells were analyzed on a fluorescence-
activated cell sorter (FACS) Calibur Flow Cytometer
(BD Bioscience, San Jose, Calif). Each analysis consisted
of 500,000 events. Data were analyzed with FlowJo
software (Tree Star, Inc, Ashland, Ore).
Cultivation of EPCs. Bone marrow and peripheral
blood were harvested 7 days after induction of ischemia.
Mononuclear cells were isolated by gradient centrifugationand cultured on fibronectin-coated plates in endothelial cell
basal medium supplemented with endothelial growth me-
dium. After 3 days, nonadherent cells were removed by
washing the plates with phosphate-buffered saline. Adher-
ent cells were used for in vitro functional analysis.
Measurement of EPC migration. In vitro migration
was evaluated in bone marrow-derived EPCs with the use
of a modified Boyden chamber. Cell suspensions (5  104
cells/well) were placed in the upper chamber, and the
lower chamber was filled with medium (control) or me-
dium containing human recombinant VEGF (50 ng/mL).
The chamber was incubated for 16 hours at 37°C. Migra-
tion activity was evaluated by counting the number of cells
on the lower chamber surface. This count was replicated in
three high-power (original magnification 400) fields per
chamber. The mean count was determined and taken as an
individual data point for each assay.
Measurement of EPC tubular incorporation. Matri-
gel was thawed and placed in four-well glass slides at room
temperature for 30 minutes to allow solidification. Dil-Ac-
LDL-labeled EPCs (2 104) were co-plated with 4 104
human umbilical vein endothelial cells and incubated at
37°C for 12 hours. The incorporation of EPCs in tubules
was determined in five random high-power (original mag-
nification 400) fields. The mean was determined and
taken as an individual data point for each assay.
Statistical analysis. Data were analyzed by one-way
analysis of variance followed by post hoc Student-Newman-
Keuls test. Statistical significance was accepted at the 95%
level (P  .05) for all analyses. Mean data are presented
with the standard deviation.
RESULTS
Blood glucose and body weight. The blood glucose
concentration was measured in all mice before the study
began to confirm a diabetic phenotype. The fasting blood
glucose was 460  36 mg/dL in treptozotocin-treated
type 1 diabetic mice, 264 14 mg/dL (P .05) in db/db
type 2mice, and 112 12mg/dL in control mice (P .05
vs type 1 and type 2 diabetic mice). Plasma insulin and
serum lipids were not measured because streptozotocin
induces profound hypoinsulinemia, and the db/db muta-
tion results in insulin resistance and an atherogenic dyslip-
idemia.18,19 Type 2 diabetic mice weighed 52  6 g
compared with 22 1 g for type 1 diabetic mice and 24
2 g for control mice (P  .05 for type 2 diabetic mice vs
type 1 diabetic mice or control mice).
Effect of ischemia on arteriogenesis. Blood flow
recovery after induction of severe hind limb ischemia was
significantly less in type 1 and type 2 diabetic mice than in
control mice. In the calf, these differences became signifi-
cant on day 14 after induction of ischemia; whereas in the
foot, significance was attained on day 21 (Fig 1). Blood
flow recovery was thus less complete in type 2 than in type
1 diabetic mice: maximal recovery reached 22% and 43% in
the foot and calf, respectively, in type 2 diabetic mice
compared with 42% and 63% in the foot and calf, respec-
tively, in type 1 diabetic mice (P  .05).
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cantly smaller diameter in the nonischemic hind limb than
type 1 diabetic or control mice (Fig 2, A and B). Collateral
artery diameter was significantly greater in the ischemic
than nonischemic hind limb in control mice. In contrast,
the collateral artery diameter was similar in the ischemic and
nonischemic hind limb of type 1 and 2 diabetic mice.
Angiography revealed the presence of a well-developed
collateral artery network in the ischemic thigh of control
mice (Fig 2, C and D). Type 1 and 2 diabetic mice both
demonstrated fewer collateral arteries visible on angiogra-
phy in the ischemic hind limb and no difference between
diabetic groups was observed. Consequently, the an-
gioscores of both diabetic groups were lower than that of
the control group.
Effect of ischemia on angiogenesis. Capillary density
was greater in the ischemic than the nonischemic hind limb
in control mice (Fig 3, A and B). A similar pattern was
evident in type 1 diabetic mice. In contrast, no difference
between the ischemic and nonischemic limbs was present in
type 2 diabetic mice; moreover, the level of capillary density
in the nonischemic hind limb in this group was less than in
the control group or type 1 diabetic mice.
Effect of ischemia on tissue integrity and muscle
histology. The rate of incisional wound healing among
the groups was similar, and all wounds healed completely
by 5 to 7 days after surgery. No toe gangrene or digit
Fig 1. Dermal blood flow in the (top) foot and (bottom) calf was
measured in the same animal at multiple times before and after
induction of ischemia (n  5 animals in each group). Flow data
represent the ratio of the ischemic to nonischemic hind limb.Mean
data are presented with the standard deviation (error bars). Pre,
Preoperative; Post, immediately postoperative, POD, postoperative
day. #P .05 for type 1 or type 2 diabetic mice vs control mice and
*P  .05 for type 2 vs type 1 diabetic mice.autoamputation was evident. Histologic evidence of mus-cle necrosis was evident in the calf muscles from the
ischemic hind limb in all groups, as shown by the pres-
ence of reduced myofiber number and size on hematox-
ylin and eosin staining (not shown). Oil Red O staining
revealed extensive fat infiltration in the ischemic calf
muscles from type 2 diabetic mice. Fat infiltration was
never observed in the ischemic hind limb of control
mice, and although present, was minimal in the ischemic
calf muscles from type 1 diabetic mice (Fig 4). Neither
fat infiltration nor muscle necrosis was observed in non-
ischemic muscles in any group.
Weights of the tibialis anterior (TA) and gastrocnemius
(GC) muscles from the ischemic hind limb were different
among the three study groups (grams): Control: TA, 1.04
0.12; GC, 0.92 0.15; type 1 diabetes: TA, 0.52  0.03*;
GC, 0.57  0.09*; and type 2 diabetes: TA, 1.90 
0.45*†; GC, 1.15  0.14† (*P  .05 type 1 or type 2
diabetic groups vs control group, †P  .05 type 2 diabetic
group vs type 1 diabetic group). As determined from
muscle histology, particularly the degree of fat, the greater
muscle weight in type 2 diabetic mice wasmost likely due to
fat infiltration rather than skeletal muscle recovery.
Effect of ischemia on muscle eNOS expression and
nitrotyrosine accumulation. Expression of eNOS in the
nonischemic thigh and gastrocnemius muscles from type 1
and type 2 diabetic mice was less than in control mice (Fig
5, A and B). After ischemia, eNOS expression significantly
decreased in the hind limb muscles of all three groups, with
one exception: expression of eNOS was not significantly
different between ischemic and nonischemic gastrocnemius
muscles from type 1 diabetic mice. Nitrotyrosine accumu-
lation was significantly greater in the ischemic than non-
ischemic gastrocnemius and thigh muscles in all study
groups (Fig 5, C and D). In the gastrocnemius muscle,
nitrotyrosine accumulation was greater in both type 1 and
type 2 diabetic mice than in control mice; moreover, nitro-
tyrosine expression in the ischemic gastrocnemius muscle
was greater in type 2 than in type 1 diabetic mice. No
differences between diabetic groups were noted in the
thigh muscles.
Effect of ischemia on eNOS expression and nitro-
tyrosine accumulation in bone marrow-derived EPCs.
Expression of eNOS in EPCs harvested from the bone
marrow from the femur and tibia of the nonischemic limb
was significantly less in type 1 or type 2 diabetic mice than
in control mice (Fig 6, A). In control mice and type 1
diabetic mice, EPCs harvested from the femur and tibia of
the ischemic hind limb demonstrated less eNOS expression
than marrow-derived EPCs from the nonischemic hind
limb. In contrast, eNOS expression in marrow-derived
EPCs from the ischemic hind limb from type 2 diabetic
mice was not different from the relatively low level present
in the nonischemic limb in this group. Nitrotyrosine accu-
mulation was greater in bone marrow-derived EPCs har-
vested from the ischemic hind limb in control mice and type
2 diabetic mice. No difference was noted in this variable in
type 1 diabetic mice (Fig 6, B).
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bone marrow and peripheral blood. The number of
EPCs (CD34, Flk-1, CD133) in the bone marrow
from the femur and tibia of the nonischemic hind limb was
similar among the three study groups. All groups also
demonstrated a greater number of bone marrow EPCs in
the femur and tibia of the ischemic than nonischemic hind
limb; however, the magnitude of this difference was signif-
icantly greater in control mice than in either diabetic group.
Moreover, the percentage of EPCs in bone marrow from
the ischemic hind limb was greater in type 2 than type 1
diabetic mice (Fig 7,A). The EPC concentration in periph-
eral blood was greater in control mice than in either dia-
betic group, and this value was significantly less in type 2
than in type 1 diabetic mice. The concentration of EPCs in
the peripheral blood increased after induction of ischemia
in control mice. In contrast, this level decreased in type 1
diabetic mice and remained unchanged in type 2 diabetic
mice. As a consequence, the peripheral blood EPC concen-
tration after induction of ischemia was significantly lower in
both diabetic groups than in control mice (Fig 7, B).
Effect of ischemia on EPC function. VEGF-induced
EPC migration was significantly greater in control mice
than in type 1 or type 2 diabetic mice (Fig 8,A). EPCs from
Fig 2. Effect of ischemia on collateral arteries was stud
each group). A,Mean data for collateral artery diameter
indicate the standard deviation. #P .05 for type 1 or ty
1 diabetic mice, and P .05 for ischemic vs nonischem
magnification 200), CD31 is stained red, smooth mus
for angioscores represent the mean number of collateral
radiograph (n  5 animals in each group). The error bar
2 diabetic mice vs control mice.D, Representative radiog
Films were obtained 28 days after induction of hind limb
mouse.both type 1 and type 2 diabetic mice showed significantlyimpaired EPC incorporation into tubular structures than in
control mice. However, the magnitude of this impairment
was greater in EPCs from type 2 than from type 1 diabetic
mice (Fig 8, C).
DISCUSSION
The present report offers the first evidence, to our
knowledge, that type 1 and type 2 diabetic mice demon-
strate different vascular responses to severe hind limb isch-
emia under identical experimental conditions. This differ-
ence was best evidenced by less effective hind limb blood
recovery in type 2 than in type 1 diabetic mice; in addition,
marked adipocyte infiltration was evident in the ischemic
hind limb muscle of type 2, but not type 1 mice. We
propose that differences in eNOS expression and oxidant
stress within ischemic muscle and in EPCs, as well as
differences in EPC function between type 1 and type 2
diabetic mice, partly explain the disparate vascular re-
sponses between groups.
Arteriogenesis is defined as the anatomic enlargement
of collateral artery diameter in response to occlusion or
obstruction of a major conduit artery.21 The physiologic
effect of this remodeling is increased collateral vascular
conductance that results in the restoration of downstream
days after the induction of ischemia (n  5 animals in
gh muscles are expressed in micrometers. The error bars
iabetic mice vs control mice, *P .05 for type 2 vs type
d limb. B, In representative photomicrographs (original
tin is stained green, and nuclei are stained blue. C, Data
ies crossing fixed points on a grid superimposed on the
cate the standard deviation. *P  .05 for type 1 or type
s are shown for control, type 1, and type 2 diabetic mice.
emia. The radiographs depict the distal one third of theied 28
in thi
pe 2 d
ic hin
cle ac
arter
s indi
raph
ischblood flow.21 This definition was fully satisfied in the
B, In these representative photomicrographs (original magnification 200), CD31 cells are stained brown.
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harvested 28 days after induction of ischemia, in which fat is stained red; counterstained with hematoxylin. TheseFig 3. Effect of ischemia on capillary density was studied 28 days after the induction of ischemia (n  5 animals
in each group). A, Data for capillary density in gastrocnemius muscle are expressed as the mean number of C31
cells per myofiber, with error bars showing the standard deviation. #P  .05 for type 1 or type 2 diabetic mice vs
control mice, *P  .05 for type 2 vs type 1 diabetic mice, and P  .05 for ischemic vs nonischemic hind limb.photomicrographs are representative of observations made in 5 animals from each group.
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arteriogenesis in this group; thus, collateral diameter was
58% greater in the ischemic vs the nonischemic hind limb,
whereas foot perfusion was restored to 65% of baseline.
The response was less clear in the diabetic groups.
Collateral artery diameter was smaller in type 2 than in type
1 diabetic mice in both the ischemic and the nonischemic
hind limb. The latter finding might indicate that the effect
of type 2 diabetes on collateral artery dimension is long-
standing, that is, that it might reflect an effect on collateral
artery development, possibly a deficiency in the responsive-
ness to shear stress, a critical stimulus for collateral devel-
opment.21
Anatomic evidence of arteriogenesis in response to
ischemia was not present in type 1 or type 2 diabetic mice,
because neither group demonstrated a difference in collat-
eral diameter between the ischemic and nonischemic hind
limbs, a finding consistent with the studies of Schiekofer et
al22 in db/db mice and Tamarat et al5 in streptozotocin-
Fig 5. Endothelial nitric oxide synthase (eNOS) and nit
ischemia in hind limb muscle (n  3 mice in each group
bars). #P  .05 for type 1 or type 2 diabetic mice vs co
P  .05 for ischemic vs nonischemic hind limb. Insets
right: control, nonischemic hind limb; control, ischemic h
nonischemic hind limb; type 2 diabetes, nonischemic h
eNOS is shown in the (A) gastrocnemius and (B)
(C) gastrocnemius and (D) thigh muscles.treated mice. However, we found that postischemic recov-ery of hind limb perfusion was clearly greater in type 1 than
in type 2 diabetic mice; that is, there was a disparity between
anatomic (collateral diameter) and physiologic (hind limb
perfusion) data. Reconciliation of this inequality cannot be
achieved from existent findings. We speculate that a more
concentrated study of collaterals, categorizing vessel di-
mension as a function of anatomic location between specific
muscles or increasing the number of collaterals measured in
each mouse, might generate anatomic evidence of arterio-
genesis in type 1 diabetic mice.
Angiogenesis is defined as the de novo generation of
capillaries in tissue downstream from the site of conduit
vessel occlusion or obstruction.21 The capillary/myofiber
ratio was less in the ischemic than in the nonischemic
gastrocnemius muscle from control mice and type 1 dia-
betic mice, indicating that postischemic angiogenesis did
not occur in either group. Type 2 diabetic mice exhibited a
ratio lower than type 1 or control mice in both ischemic and
nonischemic gastrocnemius muscles, signifying a reducing
sine expression was measured 28 days after induction of
an data are presented with the standard deviation (error
mice, *P  .05 for type 2 vs type 1 diabetic mice, and
resentative Western blots; lane designations from left to
imb; type 1 diabetes, ischemic hind limb; type 1 diabetes,
mb; type 2 diabetes, ischemic hind limb. Expression of
muscles. Nitrotyrosine expression is shown in therotyro
). Me
ntrol
, Rep
ind l
ind li
thighcapillary density in these mice. Interestingly, in contrast to
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in type 2 mice was similar between the ischemic and non-
ischemic hind limbs. One interpretation of this finding is
that the existent capillary density was protected in type 2
mice, an effect that might reflect the reduced postischemic
perfusion recovery in type 2 mice.
Tissue oxygen delivery is directly proportional to flow
rate, and one compensation for reduced oxygen delivery is
Fig 6. Expression of (A) endothelial nitric oxide synth
epithelial progenitor cells (EPCs) was measured. EPCs w
and tibia from ischemic and nonischemic hind limbs 7 da
Mean data are presented with the standard deviation (er
mice, *P .05 type 2 vs type 1 diabetic mice, and P .
Western blots; lane designations from left to right: contr
1 diabetes, ischemic hind limb; type 1 diabetes, nonische
2 diabetes, ischemic hind limb.
Fig 7. The percentage of endothelial progenitor cells
samples harvested from the femur and tibia of the nonisch
(n  6 animals per group). EPCs were characterized
fluorescence-activated cell-sorting analysis. Mean data ar
type 1 or type 2 diabetic mice vs control mice, *P  .05
vs nonischemic hind limb.increased capillary density, which yields an increased rate ofdiffusion of available capillary oxygen to cells.23 Reduced
tissue oxygen delivery also increases tissue hypoxia, the
primary stimulus for angiogenesis.24 Type 2 diabetic mice
experienced the lowest postischemic flow rate, and we
speculate that this circumstance may have provided a
greater stimulus for angiogenesis, thus precluding the re-
duction in the capillary/myofiber ratio noted in the isch-
emic gastrocnemius in type 1 diabetic and control mice. It
eNOS) and (B) nitrotyrosine in bone marrow-derived
arvested from the bone marrow derived from the femur
er induction of ischemia (n 3 animals in each group).
ars). #P  .05 type 1 or type 2 diabetic mice vs control
hemic vs nonischemic hind limb. Insets, Representative
nischemic hind limb; control, ischemic hind limb; type
hind limb; type 2 diabetes, nonischemic hind limb; type
s) was measured in bone marrow and peripheral blood
or ischemic hind limbs 7 days after induction of ischemia
34, Flk-1, CD133, and cell quantitation was by
n with the standard deviation (error bars). #P .05 for
pe 2 vs type 1 diabetic mice, and P  .05 for ischemicase (
ere h
ys aft
ror b
05 isc
ol, no
mic(EPC
emic
as CD
e show
for tyremains, however, that type 2 diabetic mice did not dem-
re sta
JOURNAL OF VASCULAR SURGERY
December 20091420 Yan et alonstrate an increased capillary/myofiber ratio in the isch-
emic vs nonischemic muscle, and in the strictest sense, we
cannot conclude that postischemic angiogenesis occurred
in this group.
EPCs are bone marrow-derived progenitor cells that
are mobilized into the peripheral blood circulation in re-
sponse to vascular injury and are essential participants in
both arteriogenesis and angiogenesis within ischemic tis-
sue.7-9 Before induction of hind limb ischemia, the per-
centage of EPCs in peripheral bloodwas lower in type 1 and
type 2 diabetic mice than in the control group, despite the
presence of similar levels of these cells in bone marrow
before induction of ischemia in all three groups. This
finding is consistent with observations previously made in
patients with type 1 diabetes, in which the percentage of
circulating EPCs was noted to be depressed, and the sever-
ity of diabetic vasculopathy was inversely correlated with
the presence of EPCs in peripheral blood.25 The percent-
age of EPCs in peripheral blood in control mice increased
39% after induction of ischemia. This percentage decreased
in type 1 and type 2 diabetic mice at this time, however,
indicating a failure of bonemarrowmobilization of EPCs in
response to hind limb ischemia in both types of diabetic
mice. Fadini et al11 and Gallagher et al10 reported a similar
finding in streptozotocin-induced type 1 diabetes in rats
and mice, respectively. To our knowledge, however, the
present report provides the first evidence of impaired EPC
Fig 8. In vitro functional assays of endothelial progenito
and nonischemic hind limbs 7 days after the induction o
each group). A, EPC migration assay. The white bars rep
the black bars represent migration in response to vascula
with the standard deviation (error bars). P  .05 for
medium, #P  .05 for type 1 or type 2 diabetic mice vs
magnification 200) of migration assay. UE lectin is sta
blue.C, Incorporation of EPCs into tubular structures (n
standard deviation (error bars). #P  .05 for type 1 o
photomicrographs (original magnification 200) of tub
images. The lower panels are fluorescent images. EPCs amobilization in type 2 diabetic mice.Impairment of EPC in vitro function has been reported
in patients with type 1 and type 2 diabetes.12,13 The present
findings indicate impaired VEGF-induced migration in
marrow-derived EPCs from type 1 and 2 diabetic mice, as
well as impaired incorporation of EPCs into tubular struc-
tures that was less effective in type 2 than in type 1 diabetic
mice.
EPCs participate in both arteriogenesis and angiogen-
esis.7 Impairment of EPC mobilization and function was
evident in both type 1 and type 2 diabetic mice, and these
effects may explain, in part, the lack of a postischemic
increase in collateral artery diameter (arteriogenesis) and
capillary/myofiber ratio (angiogenesis) in these study
groups. Huang et al26 reported compromised arteriogen-
esis and angiogenesis in KKAy mice, a genetic model of
type 2 diabetes. This group also noted significant improve-
ment in the postischemic vascular response, in association
with normalization of VEGF levels, and increased activa-
tion of eNOS and Akt after treatment with pioglitazone, a
proliferator-activated receptor-	 agonist. In this context,
the reduced EPC eNOS expression noted in both type 1
and type 2 diabetic mice may possibly have contributed to
the deficiency in arteriogenesis and angiogenesis in these
mice and that treatment with a thiazolidinedione, such as
pioglitazone, might restore these postischemic responses.
An original and important observation made in this
study was that extensive fat infiltration occurred in the
ls (EPCs) harvested from the femur and tibia of ischemic
emia and grown in culture for 3 days (n  6 animals in
t migration in response to medium alone (baseline), and
thelial growth factor (VEGF). Mean data are presented
tion in response to VEGF vs migration in response to
rol mice. B, Representative photomicrographs (original
reen, Dil-Ac-LDL is stained red, and nuclei are stained
nimals in each group).Mean data are presented with the
e 2 diabetic mice vs control mice. D, Representative
incorporation studies. The upper panels are bright field
ined red.r cel
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observed fat infiltration was a reflection of this obesity;
however, this fat infiltration only occurred in the ischemic
hind limb. We speculate that this change may reflect adipo-
genic differentiation of mesenchymal stem cells (MSCs).
MSCs are bone marrow-derived progenitor cells that, like
EPC, home to the site of vascular injury where they partic-
ipate in arteriogenesis and angiogenesis.27,28 MSCs are
pluripotent cells that can differentiate into several cell
types, including chondrocytes, adipocytes, and endothelial
cells.29 We propose that MSCs that homed to the ischemic
hind limb in type 2 mice were stimulated to an adipocytic
lineage, a fate that would effectively nullify their involve-
ment in vascular repair or adaptation.
Multiple mouse models of type 1 and type 2 diabetes
have been described. We selected the streptozotocin-
induced hypoinsulinemic mouse as a model of type 1
diabetes because it reproducibly duplicates the rapid devel-
opment of 
-cell insulinitis and subsequent hypoinsuline-
mia characteristic of human type 1 diabetes.18 An alterna-
tive model is the nonobese diabetic mouse, a genetic model
of type 1 diabetes.30,31 This mouse, however, does not
manifest full expression of the diabetic phenotype until 4 to
5 months of age, and this expression is not robust in male
mice. These conditions were deemed unacceptable because
we wished to generate hind limb ischemia at 2 to 3 months
of age in male mice to facilitate the comparison of our data
with published reports.
We selected the Leprdb/db mouse as a model for type 2
diabetes because it recapitulates the insulin resistance,
moderate hyperglycemia, and atherogenic dyslipidemia
characteristic human type 2 diabetes. A potential disadvan-
tage of the db/dbmouse is that leptin may directly affect the
proinflammatory immune responses32 and affect T-cell
function,33 phenomena that may be relevant in angiogen-
esis.34 We recognize that animal models that faithfully
duplicate human type 1 and type 2 diabetes do not exist.
We contend, however, that this caveat does not nullify the
importance of the present findings, particularly in light of
the frequency with which others have used these diabetic
mouse models.
An important methodologic caveat is themeans used to
generate hind limb ischemia. We used extirpation of the
femoral artery, a commonly used experimental model but
one that generates acute severe limb ischemia and inflam-
mation.4 This circumstance does not recreate the progres-
sive narrowing of the iliac, femoral, or popliteal arteries that
characterizes peripheral arterial disease, and a comparison
between acute vs chronic occlusion of the femoral artery in
rats indicates that muscle hypoxia and necrosis are greater
and angiogenesis less effective after acute occlusion.20 Un-
fortunately, the ameroid constrictor used to generate
chronic hind limb ischemia in that study is too large for use
in mice. It is possible that the lack of postischemic collateral
artery enlargement (arteriogenesis) noted in diabetic mice
may reflect the abrupt generation of ischemia, insofar as
collateral development appears to occur in diabetic individ-
uals with peripheral arterial disease.A second caveat to the study design was the use of the
contralateral, nonischemic hind limb as an internal control
for each mouse. It is possible that incision of a hind limb
and subsequent femoral artery extirpation therein generates
a systemic response that affects the contralateral, nonoper-
ated on hind limb. Indeed, this effect might explain why
less muscle eNOS expression was found in the contralateral,
nonischemic hind limb in type 1 and type 2 diabetic mice vs
the control group.
CONCLUSIONS
The vascular response to hind limb ischemia in diabetic
mice is contingent on the type of diabetes present. Type 2
diabetic mice demonstrated significantly less restoration of
hind limb perfusion 28 days after induction of hind limb
ischemia. Both type 1 and type 2 diabetic mice failed to
mobilize bone marrow-derived EPCs to the peripheral
circulation in response to hind limb ischemia, whereas type
2 diabetic mice displayed greater reduction of EPC func-
tion in vitro (incorporation into tubules) than type 1 dia-
betic mice.
We acknowledge the assistance of Robert Raffai in the
development of the type 1 diabetes model in our labora-
tory.
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